Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.

doi:10.1016/j.ejca.2020.05.007

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.

European journal of cancer (Oxford, England : 1990) - 1 Sept 2020

Conte Benedetta, Bruzzone Marco, Lambertini Matteo, Poggio Francesca, Bighin Claudia, Blondeaux Eva, De Laurentiis Michelino, Valle Enrichetta, Cognetti Francesco, Nisticò Cecilia, De Placido Sabino, Garrone Ornella, Gamucci Teresa, Montemurro Filippo, Puglisi Fabio, Cardinali Barbara, Fregatti Piero, Miglietta Loredana, Boccardo Francesco, Ceppi Marcello, Del Mastro Lucia

Abstract excerpt

BACKGROUND: Luminal A-like and luminal B-like subtypes have different sensitivity to (neo)adjuvant chemotherapy, but their role in predicting dose-dense (DD) efficacy in the high-risk setting is unknown. In this exploratory analysis of the Gruppo Italiano Mammella 2 (GIM2) trial, we investigated DD efficacy according to luminal-like subtypes. METHODS: Patients with node-positive early breast cancer were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Dose-Response Relationship, Drug

Share to Neoplasm Staging

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Share to Survival Analysis

Source

Open in PubMed

Identifiers

PMID: 32634760
DOI: 10.1016/j.ejca.2020.05.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.PMID 32634760Read ↗

Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.Semantic proximity Read ↗

Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast CancerSemantic proximity Read ↗

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.Semantic proximity Read ↗

Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.Semantic proximity Read ↗

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapySemantic proximity Read ↗

Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.Semantic proximity Read ↗

Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.Semantic proximity Read ↗

[Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].Semantic proximity Read ↗

Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy TrialSemantic proximity Read ↗

Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype.Semantic proximity Read ↗

Breast Cancers with a BRCA1 -like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating ChemotherapySemantic proximity Read ↗

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.